Search

Charles Edward Prussak

from San Diego, CA
Age ~70
Get Report
Also known as:
Charles E Prussak, Charles E Ttee, Chuck Prussak
Phone and address:
3905 Torrey Hill Ln, San Diego, CA 92130
(858) 794-2645
Related to:
Terry Wayne Henry, 70Brandon E Prussak, 29Mehri HedjranEdward PrussakKay Hedjran, 76Natalie R Prussak, 32Parvaneh HejranNader Hedjran, 68Rae I PrussakFarah HedjranShahla Hedjran, 74Farah Hedjran, 64
Connected to:
Shanna L Prusse, 54Matthew S Prussein, 41Brian R Prussia, 36Diann L Prussia, 72Jason P Prussiano, 40Simone L Prussien, 64Doug Prussing, 61Kelsey J Prussing, 36Ryan M Prussing, 33Maximilian E Prussner, 37

Charles Prussak Phones & Addresses

  • 3905 Torrey Hill Ln, San Diego, CA 92130 (858) 794-2645
  • Solana Beach, CA
  • La Jolla, CA
  • Del Mar, CA
  • 3905 Torrey Hill Ln, San Diego, CA 92130

Work

Company: Ucsd Jan 2010 Position: Consultant business liaison

Education

School / High School: Uc San Diego 1983 to 1988

Skills

Biotechnology • Drug Discovery • Lifesciences • Biopharmaceuticals • Drug Development • Molecular Biology • Technology Transfer • Cell Culture • Biochemistry • Cancer • Cell Biology • Pharmaceutical Industry • Clinical Trials • Life Sciences • Vaccines • Clinical Development • Cell • Immunology • Protein Chemistry • Oncology • Commercialization • Assay Development • Gmp • Microbiology • Infectious Diseases • Start Ups • Pharmacology • Venture Capital

Emails

c***[email protected]

Industries

Biotechnology

Resumes

Resumes

Charles Prussak Photo 1

Consultant Business Liaison

View page
Location:
San Diego, CA
Industry:
Biotechnology
Work:
UCSD since Jan 2010
Consultant Business Liaison
Tragen Pharmaceuticals 2003 - 2009
President & CEO
Molecular Medicine 1997 - 2003
President & CEO
Molecular Medicine BioServices 1997 - 2002
President and CEO
University of California, San Diego 1993 - 1997
Director, Gene Therapy
Education:
Uc San Diego 1983 - 1988
University of Arizona
Skills:
Biotechnology
Drug Discovery
Lifesciences
Biopharmaceuticals
Drug Development
Molecular Biology
Technology Transfer
Cell Culture
Biochemistry
Cancer
Cell Biology
Pharmaceutical Industry
Clinical Trials
Life Sciences
Vaccines
Clinical Development
Cell
Immunology
Protein Chemistry
Oncology
Commercialization
Assay Development
Gmp
Microbiology
Infectious Diseases
Start Ups
Pharmacology
Venture Capital

Business Records

Name / Title
Company / Classification
Phones & Addresses
Charles Prussak
Director, President
Roar Therapeutics
3905 Torrey Hl Ln, San Diego, CA 92130
Charles Prussak
President
TRAGEN PHARMACEUTICALS, INC
3905 Torrey Hl Ln, San Diego, CA 92130
(858) 623-2754

Publications

Us Patents

Nucleic Acids Encoding Chimeric Cd154 Polypeptides

View page
US Patent:
7495090, Feb 24, 2009
Filed:
May 23, 2002
Appl. No.:
10/154759
Inventors:
Charles E. Prussak - San Diego CA, US
Thomas J. Kipps - Rancho Santa Fe CA, US
Mark J. Cantwell - San Diego CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12N 15/62
C12N 15/12
C12N 15/00
C12N 15/63
US Classification:
536 234, 536 231, 536 235, 4352523, 4353201, 435455
Abstract:
The present invention provides for an isolated polynucleotide sequence encoding a chimeric CD154, comprising a first nucleotide sequence encoding an extracellular subdomain of non-human CD154, preferably murine CD154, that replaces a cleavage site of human CD154, and a second nucleotide sequence encoding an extracellular subdomain of human CD154 that binds to a human CD154 receptor. The present invention also provides for the chimeric CD154 that is encoded by the above-described polynucleotide sequence, an expression vector and a genetic vector comprising the polynucleotide sequence, a host cell comprising the expression vector or the genetic vector, a process for producing the chimeric CD154, and methods for utilizing the expression vectors and genetic constructs containing the chimeric CD154 polynucleotide sequences.

Nucleic Acid Molecules Encoding Tnf-Α Ligand Polypeptides Having A Cd154 Domain

View page
US Patent:
7786282, Aug 31, 2010
Filed:
Dec 6, 2001
Appl. No.:
10/006305
Inventors:
Charles E. Prussak - San Diego CA, US
Thomas J. Kipps - Rancho Santa Fe CA, US
Mark J. Cantwell - San Diego CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12N 15/12
C12N 15/11
C12N 15/63
C12N 5/10
US Classification:
536 234, 536 231, 536 235, 435 691, 435455, 435325, 4352523, 4353201
Abstract:
The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNFα and chimeric TNFα polypeptides. The former have a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNFα, wherein the encoded domain or subdomain lacks a cleavage site, and a second nucleotide sequence encoding a domain or subdomain of native TNFα that binds to a TNFα receptor. The encoded chimeric TNFα is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNFα receptor on the surface of a cell. The chimeric TNFα is therefore useful in methods for inducing apoptosis of a cell expressing a TNFα receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNFα that is expressed on the surface of the cell.

Nucleic Acids Encoding Chimeric Cd154 Polypeptides

View page
US Patent:
7928213, Apr 19, 2011
Filed:
Feb 20, 2009
Appl. No.:
12/389904
Inventors:
Charles E. Prussak - San Diego CA, US
Thomas J. Kipps - Rancho Santa Fe CA, US
Mark J. Cantwell - San Diego CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12N 15/62
C12N 15/12
C12N 15/00
C12N 15/63
US Classification:
536 234, 536 231, 536 235, 4352523, 4353201, 435455
Abstract:
The present invention provides for an isolated polynucleotide sequence encoding a chimeric CD154, comprising a first nucleotide sequence encoding an extracellular subdomain of non-human CD154, preferably murine CD154, that replaces a cleavage site of human CD154, and a second nucleotide sequence encoding an extracellular subdomain of human CD154 that binds to a human CD154 receptor. The present invention also provides for the chimeric CD154 that is encoded by the above-described polynucleotide sequence, an expression vector and a genetic vector comprising the polynucleotide sequence, a host cell comprising the expression vector or the genetic vector, a process for producing the chimeric CD154, and methods for utilizing the expression vectors and genetic constructs containing the chimeric CD154 polynucleotide sequences.

Chimeric Nucleic Acids Encoding Polypeptides Comprising Tnf Alpha, Cd70 And Fas Ligand Domains

View page
US Patent:
7964712, Jun 21, 2011
Filed:
Aug 30, 2010
Appl. No.:
12/871807
Inventors:
Charles E. Prussak - San Diego CA, US
Thomas J. Kipps - Rancho Santa Fe CA, US
Mark J. Cantwell - San Diego CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12N 15/62
C12N 15/12
C12N 15/00
C12N 15/63
US Classification:
536 234, 536 231, 536 235, 4352523, 4353201, 435455
Abstract:
The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNFα, comprising a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNFα, wherein the encoded domain or subdomain replaces a cleavage site of native TNFα, and a second nucleotide sequence encoding a domain or subdomain of native TNFα that binds to a TNFα receptor. The encoded chimeric TNFα is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNFα receptor on the surface of a cell. The chimeric TNFα is therefore useful in methods for inducing apoptosis of a cell expressing a TNFα receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNFα that is expressed on the surface of the cell.

Chimeric Cd154 Polypeptides

View page
US Patent:
8138310, Mar 20, 2012
Filed:
Mar 29, 2011
Appl. No.:
13/074638
Inventors:
Charles E. Prussak - San Diego CA, US
Thomas J. Kipps - Rancho Santa Fe CA, US
Mark J. Cantwell - San Diego CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07K 14/705
US Classification:
530350
Abstract:
The present invention provides for an isolated polynucleotide sequence encoding a chimeric CD154, comprising a first nucleotide sequence encoding an extracellular subdomain of non-human CD154, preferably murine CD154, that replaces a cleavage site of human CD154, and a second nucleotide sequence encoding an extracellular subdomain of human CD154 that binds to a human CD154 receptor. The present invention also provides for the chimeric CD154 that is encoded by the above-described polynucleotide sequence, an expression vector and a genetic vector comprising the polynucleotide sequence, a host cell comprising the expression vector or the genetic vector, a process for producing the chimeric CD154, and methods for utilizing the expression vectors and genetic constructs containing the chimeric CD154 polynucleotide sequences.

Methods Of Increasing Cancer Sensitivity To Chemotherapeutic Agents Using Chimeric Isf35

View page
US Patent:
20080318886, Dec 25, 2008
Filed:
Dec 5, 2007
Appl. No.:
11/951254
Inventors:
Charles E. Prussak - San Diego CA, US
International Classification:
A61K 31/711
A61P 35/00
US Classification:
514 44
Abstract:
A method of treating cancer by administering ISF35 or analogous constructs. The treatment can allow an increased sensitivity to treatment with a chemotherapeutic agent.

Nucleic Acid Molecules Encoding Tnf-Alpha Ligand Polypeptides Having A Cd154 Domain

View page
US Patent:
20120116052, May 10, 2012
Filed:
May 12, 2011
Appl. No.:
13/106675
Inventors:
Charles E. Prussak - San Diego CA, US
Thomas J. Kipps - Rancho Santa Fe CA, US
Mark J. Cantwell - San Diego CA, US
International Classification:
C07K 19/00
C12P 21/00
US Classification:
530350, 435 697
Abstract:
The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNFα, comprising a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNFα, wherein the encoded domain or subdomain replaces a cleavage site of native TNFα, and a second nucleotide sequence encoding a domain or subdomain of native TNFα that binds to a TNFα receptor. The encoded chimeric TNFα is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNFα receptor on the surface of a cell. The chimeric TNFα is therefore useful in methods for inducing apoptosis of a cell expressing a TNFα receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNFα that is expressed on the surface of the cell.

Method For The Purification Or Removal Of Retroviruses Using Sulfated Cellulose

View page
US Patent:
54478596, Sep 5, 1995
Filed:
Jul 16, 1993
Appl. No.:
8/093436
Inventors:
Charles E. Prussak - San Diego CA
Assignee:
Viagene - San Diego CA
International Classification:
C12N 702
C02F 142
US Classification:
435239
Abstract:
Methods and compositions useful for the separation of viruses, including retroviruses and vital vectors, from preparations are disclosed. Sulfated oligosaccharides with at least about 6. mu. moles sulfate per gram of oligosaccharide are provided. In one aspect, a sulfated oligosaccharide of the present invention may be used in the purification of a virus, such as a lipid envelope virus. The present invention also discloses methods for the removal of a contaminating virus from a preparation, such as biologic therapeutics.
Control profile
Charles Edward Prussak from San Diego, CA, age ~70 Get Report